Relationship between Cisplatin or Nedaplatin-Induced Nephrotoxicity and Renal Accumulation

Kawai, Yoshiko; Taniuchi, Saburo; Okahara, Shigeki; Nakamura, Masuhisa; Gemba, Munekazu

doi:10.1248/bpb.28.1385

Cited by 88 publications

(42 citation statements)

References 19 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been reported that cisplatinrelated nephrotoxicity develops in a dose-dependent manner in animals and humans. [30] In animal models, the S3 segment of the proximal tubule appears to be major site of renal injury. [2,18,29,31] In humans, however, damage seems to occur primarily in the distal tubule and collecting ducts.…”

Section: Discussionmentioning

confidence: 99%

Protective Effects of Vitamin C on Cisplatin-Induced Renal Damage: A Light and Electron Microscopic Study

2008

View full text Add to dashboard Cite

The present study was performed to investigate whether the chronic administration of antioxidant vitamin C provided morphological protection on cisplatin-induced renal damage. Wistar albino male rats were divided into control and two experiment groups, each consisting of six rats. Cisplatin (5 mg/kg/ month) was administered intravenously to the second and third group for three months. After the first application of cisplatin, vitamin C (8 mg/kg/day) to the third group was administered intramuscular for 3 months. At the end of the third month, the kidney specimens of the all groups were obtained. All of these kidney specimens were processed for light and electron microscopical examination. In the second group, most of the renal corpuscle lost their normal appearance and size, especially in the corticomedullary region. The most obvious changes were encountered in the proximal tubules. These changes were tubular dilation, thickening of basement membrane, loss of brush border, vacuolization, and swollenness of mitochondria in the proximal tubule epithelial cells. In addition, infiltration foci were observed mainly in the cortical region. In the third group, which was administered cisplatin plus vitamin C, although the structural damages and morphometric changes were lessened, mononuclear cell infiltration was still observed. This study suggests that the chronic administration of vitamin C may be of therapeutic benefit on cisplatin nephrotoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Effects of Vitamin C on Cisplatin-Induced Renal Damage: A Light and Electron Microscopic Study

2008

View full text Add to dashboard Cite

show abstract

“…Kawai et al 27 showed that renal accumulation of platinum when cisplatin was administered at 3.75 mg/kg was similar to that of NDP administered at 24 mg/kg, and that both drugs at these two doses induced similar effects in the kidney. It was inferred, therefore, that the nephrotoxicity of NDP was lower than that of CDDP due to lower accumulation of platinum.…”

Section: ##mentioning

confidence: 99%

Amelioration of Nedaplatin-Induced Nephrotoxicity by Continuous Infusion in Rats

et al. 2007

View full text Add to dashboard Cite

Abstract:The current experiment was conducted to evaluate whether prolongation of infusion time is useful for the amelioration of nedaplatin (NDP)-induced nephrotoxicity. Eight-week-old male rats were treated with 12 mg/kg NDP with the following dosing protocols, bolus injection, 1-or 4-hour continuous infusions (1hIF or 4hIF, respectively), and sacrificed 3 days after dosing. Urinary parameters were monitored on the day of the sacrifice, and the kidneys and femurs were removed for histopathological examination and bone marrow analysis. In the Bolus-NDP group, urine pH and specific gravity were decreased compared with the corresponding control group and glucosuria and occult blood were detected, while no abnormalities were noted in these urine parameters in the 4hIF-NDP group. Histopathological examination revealed slight to moderate renal lesions, such as single cell and/or focal necrosis in the epithelium of cortical tubules and collecting ducts in the renal papilla in the Bolus-NDP group. In the 1hIF-and 4hIF-NDP groups, there were clear reductions in the severity of renal tubular damage compared with the Bolus-NDP group, and the severity of renal tubular damage tended to reduce with increased infusion time. A TUNEL assay revealed that the numbers of TUNEL-positive cells in the 1hIF-and 4hIF-NDP groups were significantly lower than that in the Bolus-NDP group. There was a significant decrease in the number of TUNEL-positive cells in the 4hIF-NDP group compared with that in the 1hIF-NDP group. However, prolongation of the infusion time had no clear effect on the myelotoxicity of NDP. These results provide new evidence that prolongation of the infusion time is effective at minimizing the nephrotoxicity of NDP. (J Toxicol Pathol 2007; 20: 141-147)

show abstract

“…Nedaplatin is a derivative of second-generation platinum that has similar antitumor activities to Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens cisplatin with less gastrointestinal toxicity and nephrotoxicity [Kawai et al 2005;Sasaki et al 1991;Alberts et al 1997]. Also, our recent phase II study of nedaplatin plus capecitabine has shown satisfactory antitumor activity as salvage chemotherapy for cisplatin-refractory recurrent and metastatic NPC [Peng et al 2013].…”

Section: Introductionmentioning

confidence: 99%

Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens

Peng

Wang

et al. 2016

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background:In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed. Methods: A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m 2 , day 1) every 3 weeks. The body surface area (BSA) decided the dose of S-1: 40 mg twice a day when BSA < 1.25 m 2 ; 50 mg twice daily when 1.25 m 2 ⩽ BSA < 1.5 m 2 ; and 60 mg twice daily when BSA ⩾ 1.5 m 2 . Results: Treatment was well tolerated. The main hematological adverse event was neutropenia. Five patients (9.6%) had grade 3 neutropenia. Three patients were found with grade 3 anemia (5.8%). One patient was found with grade 3 thrombocytopenia (1.9%). No patient was found with grade 3 or 4 nonhematological toxicity. The rates of complete response, partial response and overall response were 3.8%, 38.5% and 42.3%, respectively. Median time to progression was 6.2 months and median survival was 14.6 months. The rates of 1-year survival and 2-year survival were 63% and 27%, respectively. Conclusions: NS chemotherapy provides a satisfactory and safe clinical activity for patients with recurrent and metastatic NPC after platinum-containing chemotherapy failed.

show abstract

Relationship between Cisplatin or Nedaplatin-Induced Nephrotoxicity and Renal Accumulation

Cited by 88 publications

References 19 publications

Protective Effects of Vitamin C on Cisplatin-Induced Renal Damage: A Light and Electron Microscopic Study

Protective Effects of Vitamin C on Cisplatin-Induced Renal Damage: A Light and Electron Microscopic Study

Amelioration of Nedaplatin-Induced Nephrotoxicity by Continuous Infusion in Rats

Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens

Contact Info

Product

Resources

About